Menelaos Pipis,Shawna M E Feely,James M Polke,Mariola Skorupinska,Laura Perez,Rosemary R Shy,Matilde Laura,Jasper M Morrow,Isabella Moroni,Chiara Pisciotta,Franco Taroni,Dragan Vujovic,Thomas E Lloyd,Gyula Acsadi,Sabrina W Yum,Richard A Lewis,Richard S Finkel,David N Herrmann,John W Day,Jun Li,Mario Saporta,Reza Sadjadi,David Walk,Joshua Burns,Francesco Muntoni,Sindhu Ramchandren,Rita Horvath,Nicholas E Johnson,Stephan Züchner,Davide Pareyson,Steven S Scherer,Alexander M Rossor,Michael E Shy,Mary M Reilly,for the Inherited Neuropathies Consortium - Rare Disease Clinical Research Network,Silvia Baratta,Paula Bray,Daniela Calabrese,Kayla Cornett,Gabrielle Donlevy,Katy Eichinger,Maria Foscan,Silvia Genitrini,Natalie Rose Grant,Tara Jones,Diana Lee,Brett A McCray,Stefania Magri,Manoj Menezes,Krista Mullen,Tina Nanji,Sara Nuzzo,Emanuela Pagliano,Roy Poh,Eun Park,Saba Sadaf,Paola Saveri,Carly Siskind,Janet E Sowden,Charlotte J Sumner,Simone Thomas,

Abstract:Abstract Mitofusin-2 (MFN2) is one of two ubiquitously expressed homologous proteins in eukaryote cells, playing a critical role in mitochondrial fusion. Mutations in MFN2 (most commonly autosomal dominant) cause Charcot-Marie-Tooth disease type 2A (CMT2A), the commonest axonal form of CMT, with significant allelic heterogeneity. Previous, moderately-sized, cross sectional genotype-phenotype studies of CMT2A have described the phenotypic spectrum of the disease, but longitudinal natural history studies are lacking. In this large multicentre prospective cohort study of 196 patients with dominant and autosomal recessive CMT2A, we present an in-depth genotype-phenotype study of the baseline characteristics of patients with CMT2A and longitudinal data (1–2 years) to describe the natural history. A childhood onset of autosomal dominant CMT2A is the most predictive marker of significant disease severity and is independent of the disease duration. When compared to adult onset autosomal dominant CMT2A, it is associated with significantly higher rates of use of ankle-foot orthoses, full-time use of wheelchair, dexterity difficulties and also has significantly higher CMT Examination Score (CMTESv2) and CMT Neuropathy Score (CMTNSv2) at initial assessment. Analysis of longitudinal data using the CMTESv2 and its Rasch-weighted counterpart, CMTESv2-R, show that over 1 year, the CMTESv2 increases significantly in autosomal dominant CMT2A (mean change 0.84 ± 2.42; two-tailed paired t-test P = 0.039). Furthermore, over 2 years both the CMTESv2 (mean change 0.97 ± 1.77; two-tailed paired t-test P = 0.003) and the CMTESv2-R (mean change 1.21 ± 2.52; two-tailed paired t-test P = 0.009) increase significantly with respective standardized response means of 0.55 and 0.48. In the paediatric CMT2A population (autosomal dominant and autosomal recessive CMT2A grouped together), the CMT Pediatric Scale increases significantly both over 1 year (mean change 2.24 ± 3.09; two-tailed paired t-test P = 0.009) and over 2 years (mean change 4.00 ± 3.79; two-tailed paired t-test P = 0.031) with respective standardized response means of 0.72 and 1.06. This cross-sectional and longitudinal study of the largest CMT2A cohort reported to date provides guidance for variant interpretation, informs prognosis and also provides natural history data that will guide clinical trial design.

DNAJB2‐related Charcot‐Marie‐Tooth disease type 2: Pathomechanism insights and phenotypic spectrum widening

Mutations in DNA2 link progressive myopathy to mitochondrial DNA instability.

P20‐1  A new locus for autosomal dominant Charcot‐Marie‐Tooth disease type 2 (CMT2L) maps to chromosome 12Q24

A New Locus for Autosomal Dominant Charcot-Marie-Tooth Disease Type 2 (CMT2L) Maps to Chromosome 12Q24

Charcot–Marie–Tooth disease type 2F associated with biallelic HSPB1 mutations

Clinical,pathological and Genetic Studies in a Chinese Charcot-Marie-Tooth Disease Type 2 Family

Charcot-Marie-tooth disease type 2A: An update on pathogenesis and therapeutic perspectives

A Novel GBF1 Variant in a Charcot-Marie-Tooth Type 2: Insights from Familial Analysis

A Novel TFG C.793c>g Mutation in a Chinese Pedigree with Charcot‐Marie‐Tooth Disease 2

Charcot-Marie-Tooth disease (CMT): distinctive phenotypic and genotypic features in CMT type 2

CMT2D neuropathy is linked to the neomorphic binding activity of glycyl-tRNA synthetase

DNAJB2 C.184c>t Mutation Associated with Distal Hereditary Motor Neuropathy with Rimmed Vacuolar Myopathy

Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A

A Novel RAB7 Mutation in a Chinese Family with Charcot-Marie-Tooth Type 2B Disease.

Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study

Mutations in the pleckstrin homology domain of dynamin 2 cause dominant intermediate Charcot-Marie-Tooth disease

Clinical and genetic features of CMT2T in Italian patients confirm the importance of MME pathogenic variants in idiopathic, late-onset axonal neuropathies

A novel mutation in the LRSAM1 gene in a family with early onset autosomal dominant Charcot-Marie-Tooth type 2P

Charcot-Marie-Tooth disease: experience from a large Italian tertiary neuromuscular center

HSJ1-related hereditary neuropathies: novel mutations and extended clinical spectrum

One Multilocus Genomic Variation Is Responsible for a Severe Charcot-Marie-Tooth Axonal Form